The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer

Maimoona Khushk, Adil Khan, Abdur Rehman, Sehrish Sheraz, Yar Muhammad Tunio, Kubra Rehman, Duaa Rehman, Moiz Ahmed, Kiran Abbas, Muhammad E Khan, Maimoona Khushk, Adil Khan, Abdur Rehman, Sehrish Sheraz, Yar Muhammad Tunio, Kubra Rehman, Duaa Rehman, Moiz Ahmed, Kiran Abbas, Muhammad E Khan

Abstract

Introduction Breast cancer is a major cause of mortality among females, worldwide. The present study was intended to evaluate the significance in the management of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in patients with breast cancer. Methodology A cohort study was conducted at the Jinnah Postgraduate Medical Center, Karachi, Pakistan from June 2020 to May 2021. All diagnosed cases of breast cancer who underwent surgical excision of tumor were eligible to partake. Patients who had metastatic breast cancer or had a recurrence were excluded. The patient's sociodemographic and clinical data were documented in a predefined pro forma. It included information about the age, sex, weight, as well as serum CEA and CA15-3. The CA15-3 and CEA levels for each patient were assessed by taking a 5ml blood sample and sending it to the laboratory for further workup. preoperatively on the second, seventh, and 28th postoperative days. Results A mean ± SD age of 52.6 ± 8.89 years was reported. Family history of breast cancer was positive in one-fourth of the patients. Nodal metastasis was negative in 114 (46.72%) patients. Three-fourth of patients had Stage II-IV with only a minority diagnosed with Stage I. The mean levels for CA15-3 in women with Stage I cancer was significantly lower on the seventh day and 28th postoperative day, compared to preoperative levels (p = 0.05). Similar associations were seen for stages II and III. Higher CEA levels were significantly associated with stage III breast cancer preoperatively (5.88 ng/ml, p = 0.05) compared to postoperative values. Conclusion The current study revealed that preoperative values of serum CEA and CA15-3 significantly reduced postoperatively. Moreover, patients with advanced cancers had significantly higher levels of both tumor markers than those with less advanced diseases. The current study highlighted the importance of regular assessment of serum CEA and CA15-3 in breast cancer patients. Both these biomarkers are substantially elevated in breast cancer patients, preoperatively. Determining the levels of serum CEA and CA15-3 pre- and postoperatively may determine the prognosis and aid in forming the most optimal patient care regime with respect to the stage and subtype of cancer.

Keywords: breast cancer; ca 15-3; cancer antigen 15-3; carcinoembryonic antigen; cea.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2021, Khushk et al.

References

    1. Centers for Disease Control and Prevention (CDC). Breast cancer screening among adult women—behavioral risk factor surveillance system, United States, 2010. Miller JW, King JB, Joseph DA, Richardson LC, Centers for Disease Control and Prevention (CDC) . MMWR Morb Mortal Wkly Rep. 2012;61:46–50.
    1. Trends in breast cancer by race and ethnicity: update 2006. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M. CA Cancer J Clin. 2006;56:168–183.
    1. Cancer incidence and mortality in Europe, 2004. Boyle P, Ferlay J. Ann Oncol. 2005;16:481–488.
    1. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Oncologist. 2007;12:20–37.
    1. Cancer mortality in India: a nationally representative survey. Dikshit R, Gupta PC, Ramasundarahettige C, et al. Lancet. 2012;379:1807–1816.
    1. Cancer patterns in Karachi (all districts), Pakistan: first results (2010-2015) from a pathology based cancer registry of the largest government-run diagnostic and reference center of Karachi. Qureshi MA, Mirza T, Khan S, et al. Cancer Epidemiol. 2016;44:114–122.
    1. Cancer incidence in Karachi, Pakistan: first results from Karachi cancer registry. Bhurgri Y, Bhurgri A, Hassan SH, et al. Int J Cancer. 2000;85:325–329.
    1. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Vizcarra E, Lluch A, Cibrián R, Jarque F, García-Conde J. Oncology. 1994;51:491–496.
    1. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Yin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Clin Chim Acta. 2018;487:363–368.
    1. Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Fu Y, Li H. Med Sci Monit. 2016;22:3154–3162.
    1. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Nam SE, Lim W, Jeong J, et al. Breast Cancer Res Treat. 2019;177:669–678.
    1. Assessment of elevated serum tumor markers carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) among patients with different subtypes of metastatic breast cancer. Taghizadeh A, Pourali L, Joudi M, et al. Middle East J Cancer. 2019;10:17–22.
    1. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. Lian M, Zhang C, Zhang D, et al. J Clin Lab Anal. 2019;33:0.
    1. Prognostic significance of CA 15-3 tumor marker in breast cancer patients. Valić A, Milas I, Mayer L, Šetić M, Matijević V, Stanec M. Libr Oncol: Croat J Oncol. 2017;45:1–8.
    1. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Ann Oncol. 2013;24:1225–1231.
    1. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Li J, Liu L, Feng Z, et al. Breast Cancer. 2020;27:621–630.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit